Meliha Melin Uygur

ORCID: 0000-0002-6569-8142
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pituitary Gland Disorders and Treatments
  • Growth Hormone and Insulin-like Growth Factors
  • Adrenal and Paraganglionic Tumors
  • Bone health and osteoporosis research
  • Bariatric Surgery and Outcomes
  • Connective Tissue Growth Factor Research
  • Glioma Diagnosis and Treatment
  • Vitamin D Research Studies
  • Gynecological conditions and treatments
  • Thyroid Disorders and Treatments
  • Diet and metabolism studies
  • Cardiovascular Health and Disease Prevention
  • Diabetes, Cardiovascular Risks, and Lipoproteins
  • Thyroid Cancer Diagnosis and Treatment
  • Body Contouring and Surgery
  • TGF-β signaling in diseases
  • Ophthalmology and Eye Disorders
  • Parathyroid Disorders and Treatments
  • Nutritional Studies and Diet
  • Inflammatory Myopathies and Dermatomyositis
  • Scoliosis diagnosis and treatment
  • Adrenal Hormones and Disorders
  • Genetic and Kidney Cyst Diseases
  • Dermatological and Skeletal Disorders
  • Cerebrovascular and Carotid Artery Diseases

Vita-Salute San Raffaele University
2023-2025

Ipsen (Spain)
2024

Cambia
2024

Recordati (Spain)
2024

Takeda (Italy)
2024

Novo Nordisk (United Kingdom)
2024

Recep Tayyip Erdoğan University
2023-2024

IRCCS Ospedale San Raffaele
2023-2024

Marmara University
2007-2023

Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi
2013-2021

The Pituitary Society established the concept and mostly qualitative parameters for defining uniform criteria Tumor Centers of Excellence (PTCOEs) based on expert consensus. Aim study was to validate those previously proposed through collection evaluation self-reported activity several internationally-recognized tertiary pituitary centers, thereby transforming 2017 definition into a validated quantitative one, which could serve as basis future objective PTCOE accreditation.An ad hoc prepared...

10.1007/s11102-023-01345-0 article EN cc-by Pituitary 2023-08-28

Abstract Purpose A series of consensus guidelines on medical treatment acromegaly have been produced in the last two decades. However, little information is available their application clinical practice. Furthermore, international standards care not published. The aim our study was to report current for therapy acromegaly, using results collected through an audit performed validate criteria definition Pituitary Tumor Centers Excellence (PTCOE). Methods Details approaches were voluntarily...

10.1007/s11102-024-01397-w article EN cc-by Pituitary 2024-06-04

Abstract Context Osteopathy and morphometric vertebral fractures (VFs) are emerging complications in acromegaly. However, the prediction of VFs this clinical setting is still a matter uncertainty, it debated whether they an early event natural history disease. Objective We aimed to evaluate prevalence determinants patients with recently diagnosed Methods enrolled 92 (43 men/49 women) on admission neurosurgery unit before transsphenoidal surgery, compared them control individuals without...

10.1210/clinem/dgac183 article EN The Journal of Clinical Endocrinology & Metabolism 2022-03-29

We aimed to evaluate the association of serum carcinoembryonic antigen (CEA) and cancer 15–3 (CA 15–3) levels with clinicopathological parameters in patients breast (BC) their efficiency for prediction recurrence. Methods: The records 482 female diagnosis followed Medical Oncology Radiation clinics Kartal Dr. Lutfu Kirdar Education Research Hospital were evaluated retrospectively. median age was 49. CEA significantly higher postmenopausal (p = 0.022). There no between CA nodal involvement...

10.1016/j.ctarc.2021.100402 article EN cc-by-nc-nd Cancer Treatment and Research Communications 2021-01-01
Adnan Batman Dilek Yazıcı Oğuz Dikbaş Kemal Ağbaht Emre Sedar Saygılı and 87 more İbrahim Demirci Nurbanu Bursa Görkem Ayas Cüneyd Anıl Mustafa Cesur Fatma Nur Korkmaz Adile Begüm Bahçecioğlu Demet Çorapçıoğlu Murat Faik Erdoğan Hayri Bostan Murat Çalapkulu Sema Hepşen Bekir Uçan Erman Çakal Bağdagül Yüksel Güler Cem Haymana Süleyman Hilmi İpekçi Selami Aydın Havva Sezer Seçil Özışık Oğuzhan Deyneli Faruk Alagöl Refik Tanakol Mustafa Eroğlu Ümmü Mutlu Hülya Hacışahinoğulları Ayşe Kubat Üzüm Canan Demir Gönül Koç Sevde Nur Fırat Tülay Omma Nurcan İnce Şefika Burçak Polat Oya Topaloğlu Cevdet Aydın Bekir Çakır Çiğdem Tura Bahadır Mehmet Güven Mehmet Sözen Alev Selek Zeynep Cantürk Berrin Çetinarslan Mustafa Aydemir Işılay Taşkaldıran Yusuf Bozkuş Özlem Turhan İyidir Filiz Ekşi Haydardedeoğlu Seda Erem Basmaz Mehmet Çağrı Ünal Tevfik Demir Ayten Oğuz Özlem Çelik Merve Yılmaz Aykut Çimşir Serdar Kayıhan Ziynet Alphan Üç Sakin Tekin Ömercan Topaloğlu Başak Özgen Saydam Yasemin AYDOĞAN ÜNSAL Özge Özer Göknur Yorulmaz Kader Uğur Sezin Doğan Çakır Mehmet Aşık Mustafa Ünübol Selin Genç Burak Andaç Mine Okur Özlem Doğan Ersen Karakılıç Gökçen Ünal Kocabaş Cem Onur Kıraç Güven Barış Cansu Meliha Melin Uygur Zafer Pekkolay Sadettin S. Ozturk Aşkın Güngüneş Eren Gürkan Lezan Keskin Kenan Çağlayan Yasemin Günay Eren İmre Selçuk Yusuf Şener Ahmet Toygar Kalkan Deniz Engin Gök Mustafa Şahi̇n

Abstract Context The aims of the study are to compare characteristics subacute thyroiditis (SAT) related different etiologies, and identify predictors recurrence SAT incident hypothyroidism. Methods This nationwide, multicenter, retrospective cohort included 53 endocrinology centers in Turkey. participants were divided into either COVID-19–related (Cov-SAT), SARS-CoV-2 vaccine–related (Vac-SAT), or control (Cont-SAT) groups. Results Of 811 patients, 258 (31.8%) Vac-SAT group, 98 (12.1%)...

10.1210/clinem/dgad235 article EN The Journal of Clinical Endocrinology & Metabolism 2023-04-25

A recent update of consensus guidelines for the management Cushing's disease (CD) included indications medical therapy. However, there is limited evidence regarding their implementation in clinical practice. This study aimed to evaluate current therapy approaches by expert pituitary centers through an audit conducted validate criteria Pituitary Tumors Centers Excellence (PTCOEs) and provide initial standard care CD. Based on activities nine international PTCOEs between 2018 2020, we...

10.1007/s11102-024-01485-x article EN cc-by-nc-nd Pituitary 2025-01-29

The primary goal of acromegaly treatment is to normalize biochemical parameters as it significantly reduces the risks complications and comorbidities associated with disease. First-line medical commonly represented by injectable somatostatin analogues (SRLs) after surgery. In June 2020, integration Transient Permeation Enhancer® technology, oral octreotide capsules (OOCs) received regulatory approval from US Food Drug Administration for long-term maintenance in patients who have responded...

10.17925/ee.2024.20.1.9 article EN touchREVIEWS in Endocrinology 2024-01-01

BACKGROUND: The Pituitary Tumors Centers of Excellence (PTCOE) concept was established to provide a multimodal approach with careful management comorbidities. Acromegaly, one the main concerns PTCOE per se, leads increased mortality rates which cardiovascular disease is an important cause. Increased skin autofluorescence (SAF) shown be associated carotid intima-media thickness (CIMT), well-established marker atherosclerosis, and consequently complications. This study aimed evaluate SAF CIMT...

10.23736/s2724-6507.23.03951-9 article EN Minerva Endocrinology 2023-06-01

<title>Abstract</title> <bold>Purpose:</bold> A series of consensus guidelines on medical treatment acromegaly have been produced in the last two decades. However, little information is available their application clinical practice. Furthermore, international standards care not published. The aim our study was to report current for therapy acromegaly, using results collected through an audit performed validate criteria definition Pituitary Tumor Centers Excellence (PTCOE)....

10.21203/rs.3.rs-4094890/v1 preprint EN cc-by Research Square (Research Square) 2024-03-18

Amaç: Sodyum fosfat (NaP) kolonoskopi hazırlığında en sık kullanılan oral preparattır.NaP kullanımına bağlı olarak hiperfosfatemi, hipernatremi, hipokalsemi ve hipopotasemi gibi yan etkiler gelişebilir.NaP'ın etkinlik güvenilirliğini göstermek amacıyla kreatinin değerleri normal olan hastalarda etki sıklığı,

10.5505/jkartaltr.2011.42204 article TR The Journal of Kartal Training and Research Hospital 2011-01-01
Coming Soon ...